FDA Approves Moderna’s First mRNA Flu Vaccine for Older Adults

Cambridge, Saturday, 8 August 2026.
On August 5, 2026, the FDA approved Moderna’s mFlusiva, cutting vaccine production lead times from six months to just two, opening a major new commercial frontier for mRNA technology.